Advertisement

Search Results

Advertisement



Your search for Alice Goodman matches 16 pages

Showing 1 - 16


solid tumors

Atezolizumab in Urothelial Cancer: Ushering in a New Standard of Care

Atezolizumab achieved excellent results in a cohort of patients with platinum-resistant urothelial cancer enrolled in a large phase II trial known as IMvigor 210.1 Overall response rates were greatly improved over those with historical controls, and responses were durable. Although expression of...

solid tumors

Improved Outcomes in Patients With Germ Cell Testicular Tumors in the Modern Era

Although patients with poor-risk metastatic testicular germ cell tumors continue to have less favorable outcomes, the bar has been raised by contemporary treatment. There is still room for improvement in managing metastatic testicular germ cell tumors, especially in poor-risk patients, but if...

solid tumors
prostate cancer

Early Quality of Life Better with Proton-beam Therapy, but Late Effects Similar to Other Treatment Modalities for Prostate Cancer

Differing patterns of patient-reported quality of life for three-dimensional (3D) conformal radiotherapy, intensity-modulated radiation therapy, and proton-beam therapy were reported in a nonrandomized comparison of three modern cohorts of patients with prostate cancer. The study was presented at...

solid tumors
prostate cancer

Stereotactic Body Radiation Therapy Produces Impressive Results in Organ-confined Prostate Cancer

Stereotactic body radiation therapy (SBRT) delivered via the CyberKnife can achieve excellent outcomes with minimal toxicity in patients with prostate cancer. Importantly, this technique delivers therapeutic doses of radiation in four to five fractions, which reduces the number of clinic visits...

solid tumors
prostate cancer

Sildenafil Improves Overall Sexual Function in Men with Prostate Cancer Treated with Radiation

For the first time, a randomized controlled trial reported improved sexual function with 6 months of prophylactic sildenafil citrate before, during, and after radiation therapy in patients with prostate cancer.1 The paper was presented at the Plenary Session during the 54th Annual Meeting of the...

solid tumors
prostate cancer

Androgen-deprivation Therapy plus Radiation Proven as Standard of Care for High-risk Prostate Cancer

A combined-modality approach of androgen-deprivation therapy plus radiation therapy achieves a substantial survival benefit over androgen-deprivation therapy alone in patients with locally advanced prostate cancer according to final analysis of an intergroup randomized phase III study conducted by...

solid tumors
prostate cancer

Did Corticosteroids Worsen Survival in Patients with Metastatic Prostate Cancer Enrolled in the AFFIRM Trial? 

A post hoc analysis of the AFFIRM trial found that on-study use of corticosteroids led to worse outcomes in metastatic castration-resistant prostate cancer regardless of whether patients were randomly assigned to enzalutamide (Xtandi) or placebo.1 On-study corticosteroid use was associated with...

solid tumors
prostate cancer

Novel Antiandrogen Shows Encouraging Phase II Results in High-risk Nonmetastatic Castrate-resistant Prostate Cancer 

Preliminary results of a phase II study suggest that a novel antiandrogen called ARN-509 is safe, well tolerated, and has promising activity in high-risk nonmetastatic castrate-resistant prostate cancer. ARN-509 is a novel, second-generation, oral antiandrogen that binds directly to the...

solid tumors
prostate cancer

Reduced Risk of PSA Failure with Adjuvant Radiotherapy vs Wait-and-see Approach in Stage T3 Prostate Cancer

Extended follow-up of the German ARO 96-02 trial shows that adjuvant radiotherapy reduces the risk of biochemical failure in men whose prostate cancer extends through the prostate capsule (stage T3), compared with a wait-and-see approach, after radical prostatectomy. Adjuvant radiotherapy reduced...

solid tumors

Surveillance Sufficient Follow-up for Most Patients with Stage I Seminoma  

Surveillance appears to be sufficient for men with stage I seminoma treated with orchiectomy, sparing patients from side effects of adjuvant radiation or chemotherapy. In a long-term study presented at the ASCO Annual Meeting,1 99.5% of men followed by surveillance alone were disease-free and alive ...

solid tumors

Long-Term Results of COU-AA-302 Confirm Abiraterone Benefit

Final results of the COU-AA-302 trial continue to support the survival benefit of abiraterone acetate (Zytiga) in men with chemotherapy-naive metastatic castration-resistant prostate cancer, often referred to as the “predocetaxel space.” “The study met the overall survival endpoint and all...

solid tumors
bladder cancer

Patients With Near-Complete Response After Induction Therapy May Be Candidates for Bladder-Sparing Therapy

Bladder-sparing approaches are typically reserved for patients with bladder cancer who have a complete response to combined modality induction therapy (radiation plus chemotherapy). A new phase II study suggests that patients with near-complete response should also be considered for bladder-sparing ...

solid tumors

Studies Evaluate Trends in the Surgical Management of Penile Cancer

A large retrospective population-based study shows that potentially fatal penile cancers are surgically undertreated in the United States and more benign penile cancers are surgically overtreated. Even though penile cancer is rare in the United States, accounting for about 1,570 new cases in 2013...

solid tumors

Novel Agents Produce Encouraging Trends in Gastric Cancer

Several novel agents targeting the HER2, C-MET, and VEGF receptors have achieved encouraging results in gastric cancer, which is the second leading cause of cancer death worldwide. Charles Fuchs, MD, of Dana-Farber Cancer Institute, Boston, reviewed these new approaches in a presentation at the...

solid tumors

ECC 2013: Molecular Sequencing Identifies Drug Targets for Cancers of Unknown Primary Origin

Cancers of unknown primary origin pose a treatment dilemma for oncologists and a great deal of anxiety for patients and their families. A study reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA39) shows that molecular profiling can identify targetable mutations in up to 80%...

solid tumors

ASCO 2013: Surveillance Sufficient Follow-up for Most Patients with Stage I Seminoma

Surveillance appears to be sufficient for men with stage I seminoma treated with orchiectomy, sparing patients from side effects of adjuvant radiation or chemotherapy. In a long-term study presented at the 2013 ASCO Annual Meeting (Abstract 4502), 99.5% of men followed by surveillance alone...

Advertisement

Advertisement



;
Advertisement